Oruka Therapeutics announced it will report Week 16 data for ORKA-001 from the EVERLAST-B Phase 2b trial on October 26, 2026.

Reps. Zoe Lofgren and George Whitesides said they introduced the “SHIELD Our Elections Act,” a bill aimed at “protect[ing] ...

VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization ...

U.S. FDA-approved Indications Libtayo is a prescription medicine used to treat: ...

Jeffries criticizes Trump’s remarks: House Democratic Leader Hakeem Jeffries said Donald Trump had “consistently” used “vile ...

Figures seeks disaster declaration: Congressman Shomari C. Figures said he sent a letter to President Trump asking the White ...

Rep. Steny Hoyer says he has asked the House and Senate Armed Services committees to investigate reports of restrictions on ...

NovaBridge Biosciences announced updated results from the Phase 1b study of givastomig, a bispecific antibody targeting ...

ULTRALIFE lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. This included lobbying on ...

In a separate case study presented yesterday, one patient with frequently relapsing MCD received 100 mg of budoprutug. The patient experienced three-year steroid-free remission and remained in ...

Steube backs bridge funding request: Rep. Greg Steube said he sent a letter to the Federal Highway Administration supporting ...

Robeco Schweiz AG has opened a new $59.7M position in $ENTG, per a new SEC 13F filing. This disclosure reflects the funds' ...